

Hepatitis D - Pipeline Review, H2 2020

<https://marketpublishers.com/r/H0ABAED0AA1EN.html>

Date: October 2020

Pages: 102

Price: US\$ 2,000.00 (Single User License)

ID: H0ABAED0AA1EN

Abstracts

Hepatitis D - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis D - Pipeline Review, H2 2020, provides an overview of the Hepatitis D (Infectious Disease) pipeline landscape.

Hepatitis D, also known as the delta virus, is an infection that causes liver to swell. It is caused by the hepatitis D virus (HDV). Symptoms include yellowing of skin and eyes, joint pain, abdominal pains, vomiting, loss of appetite and fatigue. Risk factors include receiving many blood transfusions, abusing intravenous (IV) or injection drugs and being infected while pregnant.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis D - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Hepatitis D (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis D (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis D and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 3, 1, 4 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 2 molecules,

respectively.

Hepatitis D (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis D (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Hepatitis D (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hepatitis D (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hepatitis D (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis D (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hepatitis D (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hepatitis D (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Hepatitis D - Overview

Hepatitis D - Therapeutics Development

Hepatitis D - Therapeutics Assessment

Hepatitis D - Companies Involved in Therapeutics Development

Hepatitis D - Drug Profiles

Hepatitis D - Dormant Projects

Hepatitis D - Discontinued Products

Hepatitis D - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Hepatitis D, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Hepatitis D - Pipeline by CN Bio Innovations Ltd, H2 2020
Hepatitis D - Pipeline by Eiger BioPharmaceuticals Inc, H2 2020
Hepatitis D - Pipeline by F. Hoffmann-La Roche Ltd, H2 2020
Hepatitis D - Pipeline by Globeimmune Inc, H2 2020
Hepatitis D - Pipeline by Hepion Pharmaceuticals Inc, H2 2020
Hepatitis D - Pipeline by Johnson & Johnson, H2 2020
Hepatitis D - Pipeline by Merck & Co Inc, H2 2020
Hepatitis D - Pipeline by MYR GmbH, H2 2020
Hepatitis D - Pipeline by PharmaEssentia Corp, H2 2020
Hepatitis D - Pipeline by Replicor Inc, H2 2020
Hepatitis D - Pipeline by Rodos BioTarget GmbH, H2 2020
Hepatitis D - Pipeline by SomaGenics Inc, H2 2020
Hepatitis D - Dormant Projects, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Hepatitis D, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products by Targets, H2 2020

Number of Products by Stage and Targets, H2 2020

Number of Products by Mechanism of Actions, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Routes of Administration, H2 2020

Number of Products by Stage and Routes of Administration, H2 2020

Number of Products by Molecule Types, H2 2020

Number of Products by Stage and Molecule Types, H2 2020

I would like to order

Product name: Hepatitis D - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/H0ABAED0AA1EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H0ABAED0AA1EN.html>